Needle or Drip?—Real-World Comparison of Intravenous to Subcutaneous Infliximab and Vedolizumab in the Management of Inflammatory Bowel Diseases

Abstract

Digestive Diseases and Sciences should prioritize long-term data collection, the economic implications, potential predictors, and assess serum concentrations, all of which will help clarify the overall benefits of this treatment approach.Author's contribution All authors contributed equally to conceptualization and drafting of the submitted manuscript. Data availabilityNo datasets were generated or analyzed during the current study.